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Abstract
The preventive effect of vitamin D against breast cancer can be influenced by gene 
polymorphisms. This study aimed to investigate the association between serum level 
of 25(OH) vitamin D and FTO genotype in breast cancer patients. A cross- sectional 
study was carried out on 180 newly diagnosed patients with breast cancer in Tehran, 
Iran. The blood samples were collected from the participants in order to assess the 
FTO gene rs9939609 polymorphism by the tetra- primer amplification refractory mu-
tation system (Tetra- ARMS) PCR method. The serum level of 25(OH) vitamin D was 
measured using the direct competitive enzyme- linked immunosorbent assay (ELISA) 
method. The association between vitamin D and the FTO genotype in patients with 
breast cancer was assessed after adjustment for cofounders. The frequency of TT, 
AT and AA genotypes in the breast cancer patients were 43% (n = 77), 49% (n = 89) 
and 8% (n = 14), respectively. All patients with higher than 40 ng/dl of serum 25(OH) 
vitamin D had one or two copies of FTO rs9939609 risk allele (p = 0.019). No linear 
association was found between the number of FTO risk allele and the level of serum 
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1  |  INTRODUC TION
Breast cancer (BC) is a common malignant tumour in women, ac-
counts for 10% of malignant tumours and the second prevalent after 
uterine endometrial carcinoma.1,2 BC is the leading cause of cancer 
deaths in women, and there are approximately one million new cases 
diagnosed in the world every year.3 A family history of BC is strongly 
associated with a significant increase in the risk of BC. However, fa-
milial BCs linked to high penetrant genetic mutations account for 
only about 5% of cases.4 Recent studies reported that obesity and 
excess calorie intake can increase BC risk5,6, and there is growing 
evidence that weight loss and decrease in fat consumption may lead 
to a decrease in the risk for developing BC.7,8
The fat mass and obesity- associated (FTO) gene is frequently 
reported to be associated with obesity and some recent studies 
reported that dysregulation of FTO gene expression can affect 
multiple cancer- related processes, such as cancer cell apoptosis, 
proliferation, migration, invasion, metastasis, cell- cycle and differ-
entiation in BC patients.9 A significant association between FTO 
rs9939609 polymorphism risk allele (A) and BC risk was identified in 
females with overweight.10 This association mostly relied on the role 
of FTO in specific signalling pathways including the phosphoinositide 
3- kinase/protein kinase B/ mechanistic target of rapamycin (PI3K/
AKT/ mTOR) and mitogen- activated protein kinase (MAPK) signal-
ling pathways that are associated with cell growth, cell proliferation 
and inflammatory immune responses.9,11
On the other hand, some vitamins may have a role in the pre-
vention of BC. Vitamin D and its receptor (VDR) can regulate the 
expression of cancer- related genes in a wide range of mammalian 
cell types.12,13 Growing evidence suggest that lower levels of vita-
min D may contribute to an increased risk of BC.14 Recent studies 
reported that gene polymorphisms may regulate the association 
between serum 25(OH)D and BC.15 For this, polymorphisms 
present in the FTO gene were investigated and the interactions 
between FTO genotype, BC and vitamin D serum level were re-
ported.12– 15 A recent study reported that the effect of rs9939609 
risk allele on body weight may be limited to people with insuffi-
cient vitamin D intake.10 However, the association of FTO geno-
type and serum level of vitamin D in BC patients is not yet clear. 
Hence, this study aimed to investigate the association of serum 
level of vitamin D with FTO rs9939609 polymorphism in Iranian 
BC patients.
2  |  METHODS
2.1  |  Study population and data collection
This cross- sectional study included 180 newly diagnosed patients 
with BC and performed from January 2019 to August 2020. The 
sample size was calculated using Open EPI software and similar 
previous studies.16,17 The participants were selected according 
to the inclusion criteria from the female patients referring to the 
cancer research centre of Shohadaye Tajrish Hospital in Tehran, 
Iran. The inclusion criteria included females with confirmed BC, 
diagnosed recently, age between 35 and 70 years and consent to 
participate in the study. Basic information including medical his-
tory, alcohol consumption, smoking, the level of education and 
socioeconomic factors was collected. The amount of calorie and 
vitamin D intake in the past year was assessed using a validated 
Food Frequency Questionnaire (FFQ).18 The level of physical 
activity was measured using the International Physical Activity 
Questionnaire (IPAQ) which was validated in a previous study.19 
The patient's weight and height were measured using a SECA scale 
(Alpha 882, SECA Corporation, Hamburg, Germany), and their 
height was measured using a stadiometer, respectively. The BMI 
was calculated by dividing the weight (kg) by the square of height 
(m2).
2.2  |  Genotyping
At the beginning of the study, from each participant, about 5 ml 
intravenous blood sample was collected onto an ethylenediami-
netetraacetic acid (EDTA) tube (Becton Dickinson, France) by a 
trained phlebotomist. The blood sample was stored at −70 C until 
used for further analysis. The genomic deoxyribonucleic acid (DNA) 
was extracted from the blood samples using GeneAll DNA extrac-
tion kit (Incheon, Korea) following the manufacturer's instruc-
tion. Polymerase chain reaction (PCR) was performed with 50 ng 
of genomic DNA using a PCR amplification instrument (GeneQ; 
Hangzhou Bioer Technology Co., Ltd.) and master mix DNA poly-
merase (cat. No A180301; Ampliqon). The PCR products were ex-
amined to identify rs9939609 polymorphism of the FTO gene by the 
tetra- primer amplification refractory mutation system (Tetra- ARMS) 
PCR method.
vitamin D. All patients with high serum level of 25(OH) vitamin D had one or two 
copies of FTO rs9939609 risk allele. FTO gene polymorphisms may counteract the 
beneficial effects of vitamin D in breast cancer prevention. Further studies can help to 
better understand the genetic factors predisposing to breast cancer and their effect 
on the association between vitamin D and breast cancer.
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2.3  |  Determination of serum level of vitamin D
From an aliquot (3 ml) of frozen blood sample, the serum was pre-
pared by centrifugation at 1500 g for 15 min using a Universal cen-
trifuge (Wehingen). Quantification of serum 25- hydroxy vitamin D 
was performed using the vitamin D VIDAS Kit (Marcy- l'Étoile, bio-
Mérieux, France). This kit is based on a direct competitive enzyme- 
linked immunosorbent assay (ELISA) based method. The VIDAS 
25- OH vitamin D total assay is considered as a suitable measuring 
method for vitamins D2 and D3 serum levels with a high accuracy. 
Correlation between the results from VIDAS kit with the reference 
methods of chromatography and volume spectrometry was r=0.93 
which indicated the high efficiency of this method. The levels of 
higher than 40 ng/dl of serum vitamin D were considered as high 
level, based on the previous studies on cancer- protective effects of 
vitamin D.15
2.4  |  Statistical analysis
The patients with different FTO genotypes and different level of 
serum vitamin D were compared in terms of demographic, anthro-
pometric and clinical indices using t test (for quantitative variables) 
and chi- square (for qualitative variables) methods. Then, the as-
sociation between the frequency of the risk allele A of rs9939609 
polymorphism and serum levels of vitamin D was investigated using 
the linear regression method and the effects of confounding vari-
ables including age, Stage, Pregnancy, Marriage, Family history of 
BC, Menopause and Abortion (model 2) and BMI, smoking, alcohol, 
physical activity and dietary intake of calorie, protein, carbohydrate 
and vitamin D (model 3) were adjusted. All statistical analyses were 
performed using SPSS software ver. 21.0 (IBM), and the significance 
level of p < 0.05 was considered for all analyses.
2.5  |  Ethics approval and consent to participate
All patients signed an informed consent form at baseline. This study 
was approved by the ethical committee of Shahid- Beheshti University 
of Medical Sciences (code: IR.SBMU.RETECH.REC.1398.784).
3  |  RESULTS
The frequency of TT, AT and AA genotypes were 43% (n = 77), 49% 
(n = 89) and 8% (n = 14), respectively. The distribution of demo-
graphic, anthropometric, physiological and pathological character-
istics in the BC patients based on different FTO genotypes (TT, AA 
and AT) for the rs9939609 and different serum levels of vitamin D 
are presented in Table 1. The mean age of TT carriers and AT/AA 
carriers were 59.57 (±11.66) and 57.73 (±11.11), respectively (p > 
0.05). No significant difference was found in terms of the anthro-
pometry (height, weight and BMI), breastfeeding, menopause age, 
sleep duration stage of cancer, pregnancy, marital status, family his-
tory of BC, menopause and number of abortions between the pa-
tients with TT and AA/AT genotypes. However, when serum vitamin 
D levels were assessed, significant differences were evident when 
the patients were characterized based on the pregnancy (p < 0.05) 
and abortion history (p < 0.01) (Table 1).
The distribution of the status of lifestyle and dietary intake 
among different FTO genotypes and different serum levels of vita-
min D are presented in Table 2. No significant difference was evident 
on smoking, alcohol consumption sleep duration, macronutrient/en-
ergy intake or blood serum level of vitamin D between TT and AA/
AT genotypes. Based on the assessment of serum vitamin D levels 
and macronutrient intake characteristics, it was evident that the par-
ticipants with a low level of vitamin D had a significantly (p < 0.01) 
higher daily intake of carbohydrates. All patients with higher than 
40 ng/dl of serum 25(OH) vitamin D had one or two copies of FTO 
rs9939609 risk allele (p = 0.019) (Table 2).
No linear association was identified between the number of FTO 
risk allele and the level of serum vitamin D (Table 3). The results did 
not change after adjustment for age, breastfeeding, menopause 
age, sleep duration stage of cancer, pregnancy, marital status, fam-
ily history of BC, menopause and number of abortions. The results 
remained nonsignificant after further adjustments for BMI, smoking, 
alcohol, sleep duration, physical activity and dietary intake of calo-
rie, protein, carbohydrate and vitamin D.
4  |  DISCUSSION
To our knowledge, this is the first study investigating the re-
lationship of the FTO genotype and vitamin D in BC patients. 
The results indicated that the BC patients with risk allele (A) 
of FTO rs9939609 had significantly higher levels of vitamin D. 
Recent studies focused on the associations between BC with 
the FTO polymorphisms. It is frequently reported that obesity 
can increase the risk of BC in post- menopause women,20,21 and 
there is evidence that weight loss may reduce the risk of BC.22 
However, Mojaver et al. found no significant association be-
tween the rs9939609 FTO gene and the risk of BC in Iranian 
women.23 Contradictory results were reported on the associa-
tion between FTO gene and BC which can be due to the effects 
of different factors on the association between FTO gene and 
BC. For example, Kang et al. reported that BMI status could af-
fect the association between rs9939609 polymorphism and BC 
and concluded that FTO gene polymorphism is probably associ-
ated with BC only in overweight individuals.24 Interestingly, the 
association between FTO gene polymorphism and BC has been 
reported to be influenced by the status of oestrogen receptors. 
Oestrogen may enhance BC cell proliferation by regulating FTO 
gene expression and activating the phosphatidylinositol 3-ki-
nase (PI3K)/protein kinase B (AKT) signalling pathway in oestro-
gen receptor- positive patients. A systematic review examined 
the effect of diet on FTO gene expression in the hypothalamus 
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and reported that macronutrient intake may regulate FTO gene 
expression.25 A recent case- control study by Doaei et al., found 
no significant relationship between BC and the risk allele (A) of 
FTO rs9939609 in participants with normal BMI.26 in contrast 
with Zhao et al. indicating the association of FTO rs9939609 
with BC risk.27 Mozaffarizadeh et al. reported that rs9939609 
FTO gene polymorphism was significantly associated with BC 
risk in overweight individuals.28
On the other hand, an inverse relationship between vitamin D 
levels and BC risk has been reported in several studies. Extensive 
research has been done to identify the role of vitamin D in cancer 
prevention, and it was reported that vitamin D serum levels of above 
40 ng/ml may be protective against BC.15 Mohr et al. in a meta- 
analysis of 11 case- control studies reported that individuals in the 
highest quintile of 25 (OH) vitamin D had a reduced risk of BC com-
pared with the lowest quintile and the 25 (OH) vitamin D serum level 
TA B L E  1  Distribution of demographic, anthropometric, physiological and pathological characteristics of the breast cancer patients along 




Serum vit D level
p- ValueTT (n = 77) AT/AA (n = 103)
Low vitamin D 
(n = 140)
High vitamin D 
(n = 40)
Anthropometry
Age (years) 59.57 ± 11.66 57.73 ± 11.11 0.520 57.89 ± 11.30 65.31 ± 10.49 0.920
Height (cm) 159.33 ± 5.09 160.86 ± 7.25 0.480 160.91 ± 7.21 160.42 ± 3.16 0.080
Weight (kg) 64.77 ± 9.23 71.45 ± 10.06 0.080 70.16 ± 9.79 73.71 ± 9.87 0.930
BMI (kg/m2) 25.48 ± 3.12 27.63 ± 4.46 0.120 27.13 ± 3.76 28.56 ± 3.04 0.260
Breastfeeding 
(month)
35.80 ± 31.53 38.92 ± 31.87 0.710 29.94 ± 28.17 37.53 ± 36.89 0.750
Menopause age 
(years)
54.00 ± 2.54 45.25 ± 4.64 0.190 49.20 ± 6.058 45.55 ± 5.40 0.850
Stage of cancer
1 16 (21%) 24 (23%) 0.500 43 (31%) 18 (44%) 0.410
2 35 (46%) 48 (48%) 66 (47%) 12 (31%)
3 22 (29%) 31 (29%) 29 (20%) 8 (19%)
4 4 (4%) 0 (0%) 2 (2%) 2 (6%)
Pregnancy (no.)
<4 45 (58%) 57 (56%) 0.910 71 (51%) 13 (31%) 0.030
4– 8 31 (40%) 32 (31%) 67 (47%) 18 (44%)
>8 1 (2%) 14 (13%) 2 (2%) 9 (25%)
Marital status
Single 3 (4%) 2 (2%) 0.440 6 (4%) 2 (5%) 0.400
Married 56 (72%) 82 (81%) 112 (80%) 37 (93%)
Widowed 18 (24%) 18 (17%) 22 (16%) 1 (2%)
Family history of breast cancer
First degree 4 (5%) 7 (6%) 0.800 18 (13%) 14 (31%) 0.300
Second degree 5 (7%) 10 (9%) 31 (22%) 3 (6%)
No 68 (88%) 86 (85%) 91 (65%) 23 (63%)
Menopause
Yes 75 (98%) 85 (84%) 0.320 123 (88%) 34 (86%) 0.740
No 2 (2%) 18 (16%) 7 (12%) 6 (14%)
Abortion (number)
<2 72 (94%) 91 (90%) 0.200 132 (94%) 35 (88%) 0.010
>2 4 (6%) 12 (10%) 8 (6%) 5 (12%)
FTO genotype (rs9939609)
TT 77 (54.9%) 0 (0%) 0.019
AA/AT 63 (45.1%) 40 (100%)
*Categorized according to the mean (SD) or number (%).
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of 47 ng/ml was associated with a 50% reduced risk of BC. A similar 
inverse relationship has been reported by Stoll et al. in a systematic 
review of 37 studies.14
Recent studies identified an association between serum vitamin 
D level and single nucleotide polymorphisms (SNPs) of some genes 
such as FTO gene. Vitamin D level was reported to be inversely re-
lated to obesity, and FTO gene may affect the association between 
vitamin D and obesity.10,29 In the present study, the relationship 
between FTO genotype and 25 (OH) vitamin D was examined and 
all patients with more than 40 ng/dl serum 25 (OH) vitamin D (n 
= 40) had one or two copies of the FTO rs9939609 risk allele. FTO 
gene polymorphism may counteract the beneficial effects of vita-
min D in preventing BC. Few studies were performed on the as-
sociation of FTO genotype and vitamin D. In line with the present 
study, Lourenço et al. reported that effects of FTO genotype on 
child weight gain are more pronounced among children with insuf-
ficient serum vitamin D levels.30 Another study identified that pre- 
surgery vitamin D levels influence the size of genotype effects of 
FTO rs9939609 on RYGB surgery- induced weight loss in obese pa-
tients.31 Furthermore, Mehrdad et al. found that intake of vitamin D 
from sunlight and its nutritional sources and might be solutions for 
obesity in cases with FTO rs9939609 polymorphism.32 Interestingly, 
a recent study identified that the effect of FTO rs9939609 A risk 
allele on eating behaviour and mental health may be limited to peo-
ple with insufficient vitamin D intake.10 However, another study 
on the interactions between FTO gene polymorphism, depression 
and serum vitamin D level reported that A- allele of FTO rs9939609 
polymorphism might be associated with depression independent of 
serum vitamin D level.32
Based on the available literature, we hypothesized that the A- 
allele of FTO rs9939609 have an association with vitamin D levels 
in BC patients. However, in the present study, the patients carrying 
one or two copies of the FTO rs9939609 risk allele had more than 
40 ng/dl serum 25 (OH) vitamin D. Vitamin D was reported to be 
associated with proper insulin secretion and activity,16 and lower cir-
culating 25(OH)D has been related to insulin resistance. It is possible 
that part of the positive effects of vitamin D in preventing disease is 
due to its role in insulin secretion and function. On the other hand, 
FTO variation was associated with increased reduced peripheral in-
sulin sensitivity.16 An underlying reason behind high serum level of 
vitamin D in the BC patients with the FTO risk allele can be that the 
FTO gene polymorphism may counteract the beneficial effects of vi-
tamin D in preventing BC.
This study suggested an intricate relationship between the FTO 
rs9939609 risk allele and serum 25 (OH) vitamin D level in Iranian 
BC patients. Future studies with a larger sample are needed to con-
firm these results. The underlying mechanisms of the interactions 
of the FTO gene and vitamin D should be investigated in BC. An 





Serum vitamin D level
p- ValueTT (n = 77) AT/AA (n = 103) Low vit D (n = 140) High vit D (n = 40)
Smoking
Yes 1 (2%) 1 (1%) 0.410 4 (3%) 1 (2%) 0.830
No 99 (98%) 102 (99%) 136 (97%) 39 (98%)
Alcohol consumption
Yes 2 (3%) 1 (1%) 0.110 4 (3%) 1 (2%) 0.650
No 75 (97%) 102 (99%) 136 (97%) 39 (98%)
Sleep duration (h/24 h) 7.30 ± 0.945 8.20 ± 2.15 0.780 7.73 ± 1.58 8.00 ± 1.15 0.410
Macronutrient/energy intake
Energy (kcal/day) 2258.58 ± 121.65 2263.54 ± 1106.72 0.590 2315.52 ± 1141.52 2416.18 ± 588.85 0.070
Protein (g/day) 79.51 ± 44.73 85.21 ± 46.9 0.740 83.15 ± 35.10 84.38 ± 25.92 0.100
Carbohydrate (g/day) 336.93 ± 231.70 296.9 ± 149.29 0.640 318.58 ± 184.24 317.86 ± 174.21 0.006
Total fat (g/day) 95.66 ± 66.70 90.93 ± 56.70 0.850 93.15 ± 57.09 103.75 ± 53.56 0.690
Dietary vit D intake 
(mg/day)
1.35 ± 1.11 1.34 ± 1.22 0.970 1.7 ± 1.59 2.3 ± 1.23 0.360
Blood serum
Vitamin D (ng/dl) 25.21 ± 8.86 29.06 ± 24.90 0.490 21.62 ± 9.42 58.66 ± 19.6 <0.001
TA B L E  3  Linear regression of the association between FTO risk 
allele and serum vitamin D in patients with breast cancer
B p- Value
Model 1 0.38 0.83
Model 2 0.21 0.43
Model 3 0.62 0.61
Notes: Model 1 crude. Model 2: Adjusted for age, stage of cancer, 
pregnancy, marriage, family history of breast cancer, Menopause, 
Abortion. Model 3. Further adjustments for BMI, smoking, alcohol, 
sleep duration, physical activity and dietary intake of calorie, protein, 
carbohydrate and vitamin D.
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investigation targeting the cause- effect relationship of the risk allele 
with the molecular signalling pathways such as the oestrogen signal-
ling pathways may help to understand the cause- effect relationship. 
In addition, the role of various FTO polymorphisms in vitamin D lev-
els and other biomarkers of BC should be investigated.
4.1  |  Conclusions
In this study, a high level of circulating vitamin D was associated with 
the FTO gene risk allele (A) in BC patients. It may be likely that the 
FTO gene polymorphisms may neutralize the beneficial effects of 
vitamin D in BC prevention. Further studies are needed to confirm 
these results and to identify. Further studies on the interaction of 
FTO genes and nutritional factors in BC patients can help to better 
understand the underlying mechanisms of the effects of FTO geno-
type on the role of vitamin D in BC prevention and to identify the 
genetic factors predisposing to BC and their effect on the associa-
tion between vitamin D and BC.
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